Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulant treatment

Summary

Mitral stenosis (MS) in association with atrial fibrillation (AF) is a clinical condition at high risk for systemic thromboembolism. Although oral anticoagulants greatly reduce the incidence of thromboembolism in these patients, the optimal intensity of treatment has never been tested in specific clinical trials, and current recommendations are derived from studies of nonrheuma-tic AF. In this study we tested the effectiveness of two different intensities. The study design was carried out as an open randomized prospective study in an anticoagulation clinic.

We randomized 103 patients with MS and AF to a low (target INR = 2) or moderate (target INR = 3) anticoagulation regimen. The primary end points were systemic thromboembolism, major bleeding and vascular death.

During a mean follow-up of 4.5 years, 1 systemic embolism occurred in the low intensity group (0.41 per 100 pt/yrs, CI 0.01-2.3), and 1 minor stroke occurred in the moderate intensity group (0.40 per 100 pt/yrs, CI 0.01-2.3; p = ns). Major bleeding occurred in 8 patients, with 3 in the low intensity (1.25 per 100 pt/yrs) and 5 in the moderate intensity group (2.0 per 100 pt/yrs, Incidence Rate Ratio 0.6, CI 0.1-3.1; p = ns). Total events (systemic embolism, major bleeding and vascular death) occurred in 7 low intensity patients and 8 moderate intensity patients. As expected, minor bleeding was more frequent in the moderate intensity group of patients, who actually had more intense treatment and required closer monitoring of oral anticoagulant treatment.

These data suggest that low intensity anticoagulation, as performed in an anticoagulation clinic, is effective and safe in high risk patients with MS and AF.

Keywords

Anticoagulants - mitral valve - atrial fibrillation

• References

• 1 Chesebro JH, Adams PC, Fuster V. Anti-thrombotic therapy in patients with valvular heart disease and prosthetic heart valves. JACC 1986; 8: 41B-56B.
• 2 Wood P. Disease of the heart and circulation. Philadelphia PA: JB Lippincott; 1956
• 3 Fleming HA, Bailey SM. Mitral valve disease, systemic embolism and anticoagulants. Post-grad Med 1971; 47: 599-604.
• 4 Wolf PA, Dawber TR, Thomas Jr HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingam Study. Neurology 1978; 28: 973-7.
• 5 Adams GF, Merret JD, Hutchinson WM, Pollack AM. Cerebral embolism and mitral stenosis: survival with and without anticoagulants. J Neurol Neurosurg Psychiatry 1974; 37: 378-83.
• 6 Neilson GH, Galea EG, Hassak KF. Thromboembolic complication of mitral valve disease. Aust NZ J Med 1978; 8: 372-6.
• 7 Loeliger EA, Poller L, Samama M, Thompson JM, Van den Besselaar AMHP, Vermylen J, Verstraete M. Questions and answers on pro-thrombin time standardization in oral anticoagulant control. Thromb Haemost 1985; 54: 515-7.
• 8 Van den Besselaar AMHP, Van der Meer FJM, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Nether-lands. Am J Clin Pathol 1988; 90: 685-90.
• 9 Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990; 43: 177-83.
• 10 Levine HJ, Pauker SG, Salzman EW, Eckman MH. Antithrombotic therapy in valvular heart disease. Chest 1992; 102: 435S-44S
• 11 Petersen P, Godtfredsen J, Boysen G, Ander-sen ED, Andersen B. Placebo controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complication in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989; 1: 175-9.
• 12 Stroke Prevention in Atrial Fibrillation Investigators Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527-39.
• 13 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigation (BAATAF). The effect of low-dose warfarin on the risk of stroke in patients with norheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
• 14 Turpie AGG, Gunsten J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of anticoagulant therapy after tissue heart valve replacement. Lancet 1988; 1: 1242-5.
• 15 Nishimura RA, Miller FA, Callahan MJ, Benassi RC, Seward JB, Tajik AJ. Doppler echocardiography: theory, instrumentation technique and application. Mayo Clin Proc 1985; 60: 321-43.
• 16 Khandheria BK, Tajik AJ, Reeder GS, Callahan MJ, Nishimura RA, Miller FA, Seward JB. Doppler color flow imaging: a new technique for visualization of the blood flow jet in mitral stenosis. Mayo Clin Proc 1986; 61: 623-30.
• 17 Hatle L, Angelsen B, Tromsdal A. Noninvasive assessment of atrioventricular pressure half-time by Doppler ultrasound. Circulation 1979; 60: 1096-104.
• 18 Roldan CA, Shively BK, Crawford MH. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996; 335: 1424-30.
• 19 Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M. Musolesi S on the behalf of the Italian Study on Complications of Oral Anticoagulant Therapy. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-8.
• 20 Italian Federation of Anticoagulation Clinics. A guide to oral anticoagulant treatment. Sergio Coccheri Editor. Karger, Basel. Haemostasis 1998; 28 S1 1-46.
• 21 Rosendaal FR, Cannegieter SC, Vandermeer FJM, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-7.
• 22 Roy D, Marchand E, Gagne P, Chabot M, Car-tier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112: 1039-43.
• 23 Sahai H, Kurshid A. Statistics in epidemiology: methods, techniques and applications. CRC press. 1996..
• 24 Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ 1964; 1: 209-12.
• 25 Hinton RC, Kistler JP, Fallon JT, Friedlich AL, Fisher CM. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol 1977; 40: 509-13.
• 26 Owren PA. The result of anticoagulant therapy in Norway. Arch Int Med 1963; 111: 240-7.
• 27 Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinraue H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetal R, Deykin D. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-12.
• 28 Pengo V, Legnani C, Noventa F, Palareti G. Oral anticoagulant therapy inpatients with nonrheumatic atrial fibrillation and risk of bleeding. Thromb Haemost 2001; 85: 418-22.
• 29 Pengo V, Zasso A, Barbero F, Banzato A, Nante G, Parissenti L, John N, Noventa F, Dalla Volta S. Effectiveness of fixed mini-dose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol 1998; 82: 433-7.